课题基金 / 基金详情

Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma

Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma
用于过敏性哮喘的广泛中和 (BN) 泛 IgE 超级疫苗
批准号:
9341882
负责人:
Swey-Shen Chen
金额:
$81.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-01 至 2020-02-28

项目摘要

项目成果

Swey-Shen Chen的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT/SUMMARY Immunoglobulin E (IgE) in the lung plays a key role in allergic asthmatic inflammation. Asthmatic patients also exhibit elevated serum IgE levels, which may re-equilibrate with the lung IgE pool or enhance IgE-mediated allergic asthma. A seminal finding of IgE downregulation by active IgE immunization was first reported in our lab. This led to the product concept of the mAb omalizumab, and a subsequent collaboration with the pharmaceutical industry led to FDA approval of the XolairÒ. In the proposed project, the native conformation of receptor-binding IgE loops (e.g., the XolairÒ binding FG loop epitope) are conformationally constrained in a selected thermostable b-strand pair (dubbed super-b strands) and then fused to an immunogenic and thermostable protein scaffold as a bifunctional vaccine. The use of ImiquimodÔ(IMQ, 3M, Inc.) through a safe transcutaneous route of administration, followed by vaccine IN challenge in saline, ensures that mucosal IgA and IgG subclass anti-IgE antibodies target asthmogenic lung IgE as well as the removal of serum IgE by systemic anti-IgE antibodies. This specific targeting improves safety, and is unlikely to cause type 2 hypersensitivity or chronic urticaria. In the absence of a vaccine reboost, emerging anti-IgE producing B-cells are naturally tolerized by the endogenous self-IgE recovered during the rest period as another safety feature. A “just-in-time” vaccine reboost is required to break self-IgE tolerance to protect against allergen re-exposure. The lack of persistent IgE suppression preserves IgE competence for parasitic defenses. Our three aims are: Aim 1: Study immunogenicity of human FG supersite vaccine in rodents: location, duration, and efficacies. Aim 2: Evaluate therapeutic vaccination in alleviating IgE-mediated asthmatic inflammation and AHR in rodent models. Aim 3: Evaluate therapeutic vaccination in alleviating IgE-mediated asthmatic inflammation and AHR in rhesus macaques.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Galectin-3 with novel drugs for treatment of eczema
  • 批准号:
    7748108
  • 项目类别:
  • 资助金额:
    $40.16万
  • 财政年份:
    2009
  • 负责人:
    Swey-Shen Chen
  • 依托单位:
Bi-functional Therapeutics for Allergy-BFTA
  • 批准号:
    7668324
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2009
  • 负责人:
    Swey-Shen Chen
  • 依托单位:
Allergy Protection by Active IgE B Cell Vaccines
  • 批准号:
    6693007
  • 项目类别:
  • 资助金额:
    $29.99万
  • 财政年份:
    2003
  • 负责人:
    Swey-Shen Chen
  • 依托单位:
Allergy Protection by Active IgE B Cell Vaccines
  • 批准号:
    6585616
  • 项目类别:
  • 资助金额:
    $25.31万
  • 财政年份:
    2003
  • 负责人:
    Swey-Shen Chen
  • 依托单位:
海外基金